N-(3-甲氧基苄基)环丙胺 | 625437-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-甲氧基苄基)环丙胺
• 中文别名: 间甲氧基苄基环丙基胺
• 英文名称: N-(3-methoxybenzyl)cyclopropanamine
• 英文别名: cyclopropyl-(3-methoxy-benzyl)-amine；N-(3-methoxybenzyl)cyclopropaneamine；N-[(3-methoxyphenyl)methyl]cyclopropanamine
• CAS: 625437-31-2
• 化学式: C₁₁H₁₅NO
• mdl: MFCD07409182
• 分子量: 177.246
• InChiKey: NUPAMNLYORQZRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  N-(3-甲氧基苄基)环丙胺 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 3-(4-(1H-pyrazol-4-yl)phenyl)-1-cyclopropyl-1-(3-methoxybenzyl)urea
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors

  摘要：

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (similar to 7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

  DOI：

  10.1021/jm400062r
• 作为产物：
  描述：

  在 sodium tetrahydroborate 作用下， 反应 1.0h， 生成 N-(3-甲氧基苄基)环丙胺
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors

  摘要：

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (similar to 7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

  DOI：

  10.1021/jm400062r

文献信息

• [EN] NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE LA 1,2,3,6-TETRAHYDROPYRIDINE 3,4-DISUBSTITUEE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004096769A1

  公开（公告）日：2004-11-11

  The invention relates to novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  本发明涉及新型的3,4-二取代-1,2,3,6-四氢吡啶衍生物及相关化合物，以及它们作为活性成分用于制备药物组合物的用途。本发明还涉及相关方面，包括制备这些化合物的方法、含有一种或多种这些化合物的药物组合物，尤其是它们作为肾素抑制剂的用途。
• Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities
  作者：Enrico Perspicace、Liliana Cozzoli、Emanuele M. Gargano、Nina Hanke、Angelo Carotti、Rolf W. Hartmann、Sandrine Marchais-Oberwinkler

  DOI：10.1016/j.ejmech.2014.06.036

  日期：2014.8

  osteoporosis. Herein, we describe the design, the synthesis and the biological evaluation of 24 new 17β-HSD2 inhibitors in the 5-substituted thiophene-2-carboxamide class. Structure–activity and structure–selectivity relationships have been explored by variation of the sulfur atom position in the central core, exchange of the thiophene by a thiazole, substitution of the amide group with a larger moiety, exchange

  17β羟基类固醇脱氢酶2型（17β-HSD2）负责将高活性的雌二醇（E2）和睾酮（T）的氧化到更弱的雌酮（E1）和Δ 4雄甾烯-3,17-二酮（Δ 4-AD）。由于17β-HSD2存在于骨骼中，并且由于雌二醇和睾丸激素能够诱导骨骼形成并抑制骨骼吸收，因此抑制这种酶可能是治疗骨质疏松症的一种新的有希望的方法。在本文中，我们描述了24种新型的5取代噻吩-2-羧酰胺类17β-HSD2抑制剂的设计，合成和生物学评估。通过改变中心核中硫原子的位置，噻唑被噻唑交换，酰胺基被较大部分取代，N-甲基酰胺基与生物等排物交换，探索了结构-活性和结构-选择性之间的关系。像N-甲基磺酰胺-甲基硫代酰胺和酮，以及噻吩核心的2和3位被烷基和苯基取代，从而生成2,3,5-三取代的噻吩衍生物。在人和小鼠的酶上评估了这些化合物。从这项研究中，鉴定出一种在人和小鼠17β-HSD2酶中均有效的新型选择性化合物，化合物21（IC
• [EN] NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE TETRAHYDROPYRIDINE EN TANT QU'INHIBITEURS DE RENINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004002957A1

  公开（公告）日：2004-01-08

  The invention relates to novel tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  该发明涉及新型四氢吡啶衍生物及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组合物，特别是它们作为肾素抑制剂的用途。
• Design, Synthesis, and Structure–Activity Relationship of Economical Triazole Sulfonamide Aryl Derivatives with High Fungicidal Activity
  作者：Jian Lin、Si Zhou、Jun-Xing Xu、Wen-Qiang Yao、Ge-Fei Hao、Yi-Tao Li

  DOI：10.1021/acs.jafc.9b07887

  日期：2020.6.24

  Plant fungal diseases have caused great decreases in crop quality and yield. As one of the considerable agricultural diseases, cucumber downy mildew (CDM) caused by pseudoperonospora cubensis seriously influences the production of cucumber. Amisulbrom is a commercial agricultural fungicide developed by Nissan Chemical, Ltd., for the control of oomycetes diseases that is highly effective against CDM

  植物真菌病害已导致作物质量和单产大幅下降。由于相当大的农业疾病之一，黄瓜霜霉病（CDM）引起的霜霉病严重影响黄瓜的产量。Amisulbrom是由Nissan Chemical，Ltd.开发的商业性农业杀菌剂，用于控制对CDM高度有效的卵菌病。但是，由于引入了溴吲哚环，因此合成合成磺胺溴胺具有很高的成本。此外，持续使用氨磺胺可能会增加耐药性发展的风险。因此，迫切需要开发具有新型支架的活性杀真菌剂，但抗CDM的成本较低。在这项研究中，设计，合成和筛选了一系列1,2,4-三唑-1,3-二磺酰胺衍生物。化合物1j苯环糊精具有可比的杀真菌活性，但价格低廉且环保。它有可能被开发为对抗CDM的新型杀菌剂。对结构-活性关系的进一步研究显示了1,2,4-三唑-1,3-二磺酰胺的结构要求以及对具有高杀真菌活性的N-烷基苄胺基团的适当修饰。这项研究将为设计新颖，价格低廉的高活性铅化合物提供强有力的指导。
• [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2003093267A1

  公开（公告）日：2003-11-13

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯衍生物（I）及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，尤其是它们作为肾素抑制剂的用途。